US92790C1045 - Common Stock
VIRIDIAN THERAPEUTICS INC
NASDAQ:VRDN (10/11/2024, 8:00:02 PM)
After market: 23.63 0 (0%)23.63
+1.63 (+7.41%)
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. The company is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
VIRIDIAN THERAPEUTICS INC
221 Crescent Street, Bldg. 17, Suite 401
Waltham MASSACHUSETTS 80301
P: 16172724600
CEO: Jonathan Violin
Employees: 94
The results are also promising for the next-generation version of that drug.
Here you can normally see the latest stock twits on VRDN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: